Quantcast

Latest 5-HT3 antagonist Stories

2011-11-02 09:10:45

Among the most commonly used treatments for IBS, a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers Among the most commonly used treatments for irritable bowel syndrome — which affects as many as 20 percent of the United States population — a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials. The study, for presentation at the American...

2011-07-11 07:33:00

WARREN, N.J., July 11, 2011 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm® technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR"), announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners. The Company made the strategic decision to reacquire the commercial rights to Zuplenz from Strativa...

2011-07-06 08:35:00

CALIFON, NJ, July 6, 2011 /PRNewswire/ - PediatRx, Inc. ("PediatRx") (OTCBB: PEDX), a hospital specialty company with a current focus on oncology supportive care, has secured all of the state licenses currently necessary to sell GRANISOL directly to wholesalers and distributors in the U.S.  Sales are now being fulfilled directly by Integrated Commercialization Solutions, Inc. ("ICS"), one of the country's largest third-party logistics providers for pharmaceutical products. ICS is...

2011-06-08 05:00:00

LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48...

2011-06-01 08:00:00

GRANISOL's co-pay program covers patient out-of-pocket costs for non-Medicare and non-Medicaid patients CALIFON, NJ, June 1, 2011 /PRNewswire/ - PediatRx, Inc. (OTCBB: PEDX), a hospital specialty company with a focus on oncology supportive care, recently polled a representative sample of approximately 70 US oncologists and other physician specialists and found that the majority (78%) viewed "no patient out-of-pocket costs" as a motivating factor for prescribing GRANISOL. GRANISOL...

2011-05-05 15:19:00

Oncologists report that patient out-of-pocket costs can impact form of dosage CALIFON, NJ, May 5 /PRNewswire/ - PediatRx, Inc. (OTCBB: PEDX), a hospital specialty company with a focus on oncology supportive care, released poll data today showing that 98% of physician respondents said at least some of their patients are using co-pay assistance programs for cancer-related prescription medications. The poll was conducted by PediatRx in collaboration with Sermo and all respondents were...

2011-04-25 07:00:00

Fear of nausea a significant issue and often not discussed with healthcare providers CALIFON, NJ, April 25 /PRNewswire/ - PediatRx, Inc. (OTCBB: PEDX) today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects.(1-9 )The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous...

2011-02-01 08:00:00

Patients could instantly save up to $200 off the cost of their co-pay CALIFON, NJ, Feb. 1 /PRNewswire/ - PediatRx Inc. (OTCBB: PEDX) is pleased to announce the launch of a co-pay assistance program* to support use of  GRANISOL. This unique program allows patients to instantly save up to $200 off their co-pay each time they are prescribed GRANISOL. There are various ways in which the program can be accessed. A mobile phone texting version allows patients and caregivers to text...

2011-01-06 08:00:00

CALIFON, NJ, Jan. 6 /PRNewswire/ - Hospital specialty pharmaceutical company PediatRx Inc. ("PediatRx") began trading under the symbol OTCBB:PEDX following a merger with its wholly-owned subsidiary, effective December 28, 2010. The initial PediatRx therapeutic area of focus is cancer and associated conditions/supportive care. PediatRx has acquired GRANISOL(TM), the only FDA-approved liquid oral granisetron, used for the prevention of nausea and vomiting (emesis) associated with...

2010-10-13 13:22:10

Press release from PLoS Medicine In research published this week in PLoS Medicine, Stephen Freedman (University of Toronto) and colleagues performed a cost analysis of the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis and found that this treatment could provide substantial economic, as well as clinical, benefit. The researchers analyzed the costs of the administration of oral ondansetron in both the US and...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related